Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz

Core Insights - Omeros Corporation has secured a significant deal with Novo Nordisk valued at approximately $2.1 billion for its phase 2 asset, zaltenibart, aimed at treating rare blood and kidney disorders [2] - Analysts on Wall Street are optimistic about Omeros, with HC Wainwright assigning a Buy rating and a price target of $9 for the company's shares [3] Company Overview - Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics, particularly for orphan indications targeting immunologic diseases [4] Product Pipeline - The lead product candidate of Omeros is Narsoplimab, which is being developed for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy [3] - Omeros is also developing OMS1029, which has successfully completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 and lectin pathway disorders [3]